How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes

Boni-Schnetzler, M. and Donath, M. Y.. (2013) How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes. British journal of clinical pharmacology, Vol. 76, H. 2. pp. 263-268.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6338605

Downloads: Statistics Overview


Metabolic diseases are associated with activation of the innate immune system in various tissues and characterized by elevated inflammatory factors and the presence of immune cells. Type 2 diabetes develops when islet beta cells are deficient in producing sufficient insulin to overcome peripheral insulin resistance. Intra-islet IL-1beta activity diminishes beta cell function and survival and governs islet inflammation. Targeting the IL-1 system with the IL-1 receptor antagonist IL1Ra improved insulin secretion, glycaemia and reduced systemic inflammation in a proof of concept study with patients with type 2 diabetes. Currently, long lasting and specific IL-1beta blocking antibodies are being evaluated in clinical trials and this may lead to a novel cytokine-based treatment for type 2 diabetes.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Diabetes Research (Donath)
UniBasel Contributors:Donath, Marc
Item Type:Article, refereed
Article Subtype:Further Journal Contribution
Note:Publication type according to Uni Basel Research Database: Journal item
Related URLs:
Identification Number:
Last Modified:10 Apr 2015 09:13
Deposited On:10 Apr 2015 09:13

Repository Staff Only: item control page